Cargando…
Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma
BACKGROUND: Checkpoint-blockade immunotherapy targeting programmed cell death protein 1 (PD-1) has recently shown promising efficacy in hepatocellular carcinoma (HCC). However, the factors affecting and predicting the response to anti-PD-1 immunotherapy in HCC are still unclear. Herein, we report th...
Autores principales: | Zheng, Yi, Wang, Tingting, Tu, Xiaoxuan, Huang, Yun, Zhang, Hangyu, Tan, Di, Jiang, Weiqin, Cai, Shunfeng, Zhao, Peng, Song, Ruixue, Li, Peilu, Qin, Nan, Fang, Weijia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6651993/ https://www.ncbi.nlm.nih.gov/pubmed/31337439 http://dx.doi.org/10.1186/s40425-019-0650-9 |
Ejemplares similares
-
Anti–PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection–Related Advanced Hepatocellular Carcinoma: A Literature Review
por: Li, Bin, et al.
Publicado: (2020) -
Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome
por: Temraz, Sally, et al.
Publicado: (2021) -
A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin
por: Zheng, Yi, et al.
Publicado: (2018) -
Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma
por: Dai, Xiaomeng, et al.
Publicado: (2021) -
Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers
por: Mao, Jinzhu, et al.
Publicado: (2021)